The diagnosis of SLE is made challenging by the heterogeneous spectrum of clinical manifestations, multi-organ involvement, and unpredictable disease course with intermittent signs and symptoms.

This heterogeneity has resulted in clinical division of SLE into manifestations characterized by specific management approaches. Lupus nephritis (LN) and neuropsychiatric lupus (NP SLE) are two of ...

Clinical Features and Diagnosis of Late-onset SLE Of interest, the clinical manifestations of late-onset SLE have been found to be comparable in patients with late-onset disease, independent of ...

In the Phase IIa clinical study in SLE patients completed in the US, KPG-818 was well tolerated and demonstrated promising preliminary efficacy in SLE patients with cutaneous manifestations.

Magnetic resonance imaging (MRI) findings such as inflammatory-type lesions and myelopathies are significantly associated with attribution of neuropsychiatric (NP) events to systemic lupus ...

US Rheumatologists Believe Biogen’s Litifilimab Is the Leading SLE Pipeline Asset Poised to Offer Improvement Over Benlysta and Saphnelo Based on Clinical Trial Data ...

The TOPAZ studies will last about a year and a half and include around 20 visits to the study site and may include follow-up telephone calls The TOPAZ studies are being conducted in more than 25 ...

Treatment of Late-onset SLE The basic principles on which therapeutic strategies rest are the same regardless of age at disease onset. However, as elderly patients may be on multiple other ...

HEFEI, China, April 28, 2025 /PRNewswire/ -- Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has ...